1. Development of Carcinoid Tumour in Hormonally Treated Adenocarcinoma of the Prostate 
Joery P.F. Molenaar, Anique Baten, Willeke A.M. Blokx, Arjen Hoogendam 
European Urology 
Volume 56, Issue 5, Pages (November 2009)
DOI: /j.eururo
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
Positron emission tomography–computed tomography (PET-CT) scan showing multiple fluorodeoxyglucose (FDG)–positive lesions of varying size spread throughout the liver, increased activity in the corpus of L5 and midthoracic spine, and increased accumulation of FDG in the right lung hilus.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
(A) Hematoxylin-eosin (HE) staining of liver, ×200: central fields of cubic nonatypical cells, clearly smaller than neighbouring hepatocytes; (B) keratin/cam 5.2 staining, ×400: liver cells and bile duct (top right) strongly positive, stained colouring of tumour cells; (C) chromogranin staining, positive in cytoplasm of cells, indicating neuroendocrine differentiation; (D) CD56 demonstrates predominantly membranous staining, indicating neuroendocrine differentiation; (E) negative prostate-specific antigen (PSA) staining.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Octreotide scan showing physiological activity in spleen, kidneys, and bladder and irregular, slightly increased uptake accumulation in digestive tract. Multiple lesions in liver, one of which shows larger site of uptake caudolateral. Multiple small lesions in lungs/mediastinum, one of which shows larger site of uptake in right lung hilus. Octreotide uptake in low thoracic vertebrae and anterolateral in middle ribs on both sides.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions